JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients
Authors:
- 14 March 2022
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 122 (08) , 1333-1340
Abstract
The objective of this study was to assess the risk of arterial thrombosis in patients who harbor the JAK2V617F allele burden ≥1% detected during workup for myeloproliferative neoplasms (MPNs). We conducted a large cross-sectional analysis consisted of 5,220 patients who were tested for JAK2V617F and 1,047,258 people matched in age from health care insurance provider, taking into account age, sex, hypertension, diabetes, atrial fibrillation. Compared with noncarriers, mutation carriers were older, less likely to be current or past smokers and had lower body mass index. There was no significant difference between the groups regarding myocardial infarction and peripheral vascular disease. However, JAK2V617F ≥1% at age 34 to 54 years was associated with eightfold more likely to have transient ischemic attack (TIA)/stroke history unrelated to hypertension, diabetes, or atrial fibrillation. Association of JAK2V617F with TIA/stroke was also observed in the older age group, albeit a weaker association and not statistically significant. Prevalence of TIA/stroke was higher in patients with JAK2V617F negative, with odds ratio of 3.93 when compared with the general population after confounder adjustments. Further research is warranted to verify the relation between allele burden of JAK2V617F mutation and TIA/stroke and the role of JAK2V617F per se as a risk factor for arterial thrombosis in the absence of overt MPN. Also, consideration should be paid to the screened group with JAK2V617F negative due to the high incidence of TIA/stroke among them in comparison to the general population.Keywords
This publication has 31 references indexed in Scilit:
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis)Blood, 2012
- Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysisBlood, 2012
- Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosisThrombosis Research, 2011
- Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative NeoplasmsThrombosis, 2011
- JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia veraExperimental Hematology, 2009
- JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive PatientsMayo Clinic Proceedings, 2008
- Thrombophilia Screening: Little Role for the JAK2V617F MutationMayo Clinic Proceedings, 2008
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia, 2007
- Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disordersJournal of Thrombosis and Haemostasis, 2007
- Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersBlood, 2006